New Nordic | Active Liver Tablets | Pack of 2 x 30s

Product Information

Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371:387–94. Gallagher C, Sanders P, Wong CX. Anticoagulation for atrial fibrillation in cirrhosis of the liver: are low-dose non-vitamin K oral anticoagulants a reasonable alternative to warfarin? J Am Heart Assoc. 2019;8:e012102.

Milk thistle extract (Silybum marianum, L.), globe artichoke extract (Cynara scolymus, L.), choline hydrogen tartrat, filling agent (microcrystalline cellulose), turmeric extract (Curcuma longa, L), disintegrator (crosslinked sodiumcarboxymethylcellulose), coating agents (vegetable magnesiumsalts of fatty acids, hydroxypropylmethyl cellulose, gum Arabic, talcum, glycerine), anti-caking agent (siliciumdioxide), modified potato starch. NASH with moderate fibrosis (fibrosis stage 2): Inflammation and damage have caused some scarring. Your liver is probably still working well and the damage can mostly be repaired. Ribeiro de Avilar, C, et al. (2017).Effect of silymarin on biochemical indicators in patients with liver disease:Systematic review with meta-analysis. Hospitalized patients with cirrhosis have a 0.5–6.3% incidence of newly-diagnosed PE or DVT, similar to those without liver disease [ 29]. Validated risk stratification scores that predict VTE within hospitalized patients, also appear to accurately predict VTE among hospitalized patients with CLD [ 30]. Interestingly, a recent meta-analysis has shown that the risk of all VTE events was higher in patients with cirrhosis than in controls with an odds ratio (OR) of 1.7 [ 15]. Moreover, patients with cirrhosis and VTE may have increased mortality over 30 days as compared to those with VTE without cirrhosis [ 31, 32]. Nevertheless, prophylactic anticoagulation for VTE in hospitalized cirrhotics is significantly lower than in non-cirrhotics [ 33].Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietiläinen KH, Lundbom N, Rissanen A, Lassila R, Yki-Järvinen H. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liverdisease. Liver Int. 2011;31:176–83. Direct oral anticoagulants (DOACs) have become the first-line drugs in the treatment of non-valvular AF (NVAF) and VTE with proven similar or better efficacy than vitamin-K antagonists (VKAs) such as warfarin and significantly reduced risk of major bleeding, mainly intracranial haemorrhage (ICH) [ 3, 4]. However, patients with liver disease and cirrhosis were excluded from pivotal randomized controlled trials (RCTs) of DOACs and evidences in this particular setting are limited [ 5]. Potze W, Siddiqui MS, Boyett SL, Adelmeijer J, Daita K, Sanyal AJ, Lisman T. Preserved hemostatic status in patients with non-alcoholic fatty liver disease. J Hepatol. 2016;65:980–7. Milk thistle seems to be safe. Yet, some people have reported GI symptoms or allergic reactions after taking it.

Your liver has little or no long-term damage or scarring and is probably still working well. By eating healthily, doing plenty of physical activity and keeping your weight in a healthy range you have a good chance of repairing any damage and reversing your NAFLD.Lab studies suggest that silymarin helps regenerate liver tissue, bring down inflammation, and protect liver cells from damage by acting as an antioxidant. Human studies have been mixed on its benefits, though. Kunk PR, Collins H, Palkimas S, Intagliata NM, Maitland HS. Direct oral anticoagulants in patients with cirrhosis appear safe and effective. Blood. 2016;128:3827.